<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9521">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742885</url>
  </required_header>
  <id_info>
    <org_study_id>111756</org_study_id>
    <nct_id>NCT00742885</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1557484A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK
      Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain</measure>
    <time_frame>At Day 0 and Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia/05/2005 antigen (A/Indonesia).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for H5N1 HI Antibodies</measure>
    <time_frame>At Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI Antibody Seroconversion Factors for H5N1 HI Antibodies</measure>
    <time_frame>At Day 0 and Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroprotected for H5N1 HI Antibodies</measure>
    <time_frame>At Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain</measure>
    <time_frame>At Day 0, Day 21 and Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for H5N1 HI Antibodies</measure>
    <time_frame>At Day 21 and Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factors for H5N1 HI Antibodies</measure>
    <time_frame>At Day 21 and Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for H5N1 HI Antibodies</measure>
    <time_frame>At Day 0, Day 21 and Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers for Serum Anti-H5N1 Neutralising Antibodies</measure>
    <time_frame>At Day 0, Day 42 and Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Serum Anti-H5N1 Neutralising Antibodies</measure>
    <time_frame>At Day 42 and Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a subject with a minimum 4 fold increase in titer at post-vaccination for neutralising antibody response at Days 42 and 182.
The H5N1 vaccine strain included A/Indonesia antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</measure>
    <time_frame>At Day 0, Day 7 and Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical and haematological parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), basophils (BAS) and blood urea nitrogen (BUN ). Categories = unknown, below, within, or above the normal ranges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</measure>
    <time_frame>At Day 0, Day 7 and Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical and haematological parameters assessed in blood samples include creatinine (CREA), eosinophils (EOS), hemoglobin (HB) and hematocrit (HC).
Categories = unknown, below, within, or above the normal ranges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</measure>
    <time_frame>At Day 0, Day 7 and Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical and haematological parameters assessed in blood samples include lymphocytes (LYM), monocytes (MON) and neutrophils (NEU).
Categories = unknown, below, within, or above the normal ranges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Normal or Abnormal Urine Values</measure>
    <time_frame>At Day 0, Day 7 and Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine parameters assessed were blood, glucose, protein and urobilinogen. Categories = negative, positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day post vaccination period (Days 0-6) after any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed were pain, redness and swelling/induration. Any=any solicited local symptom reported regardless of their intensity. Grade 3 pain= significant pain at rest that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness and swelling/induration=redness and swelling/induration above 100 millimetres (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day post vaccination period (Days 0-6) after any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed were fatigue, headache, joint pain, muscle aches, shivering, increase sweating and fever. Any=any solicited general symptom reported regardless of their intensity grade or their relationship to vaccination. Any fever was ≥ 38.0 degrees celsius (°C). Grade 3 = general symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever was≥ 39.0°C. Related= general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 21-day (Days 0-20) following vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</measure>
    <time_frame>From Day 0 to Day 83 following vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Medically-significant Conditions (MSCs)</measure>
    <time_frame>During the 182-day (Days 0-181) post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>MSCs were defined as AEs with a medically-attended visit (s) i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (Day 0 to Day 181)</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza A (H5N1) 20-40 Years Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza A (H5N1) 41-64 Years Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted</intervention_name>
    <description>All subjects will receive 2 doses administered as an intramuscular (IM) injection.</description>
    <arm_group_label>Influenza A (H5N1) 41-64 Years Group</arm_group_label>
    <arm_group_label>Influenza A (H5N1) 20-40 Years Group</arm_group_label>
    <other_name>PumarixTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male and female adults 20 to 64 years of age at time of the first
             vaccination, inclusive.

          -  Good general health as assessed by medical history and physical examination.

          -  Access to a consistent means of telephone contact, which may be either in the home or
             at the workplace, land line or mobile, but NOT a pay phone or other multiple-user
             device.

          -  Written informed consent obtained from the subject.

          -  Comprehension of the study requirements, expressed availability for the required
             study period, and ability to attend scheduled visits.

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

        Exclusion Criteria:

          -  Presence of significant acute or chronic, uncontrolled medical or psychiatric
             illness.

          -  Presence or evidence of substance abuse or of neurological or psychiatric diagnoses
             which, although stable, are deemed by the investigator to render the potential
             subject unable/unlikely to provide accurate safety reports.

          -  Diagnosed with cancer, or treatment for cancer within 3 years.

          -  Presence of an axillary temperature &gt;= 37.5 °C, or acute symptoms greater than &quot;mild&quot;
             severity on the scheduled date of first vaccination.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including
             history of human immunodeficiency virus (HIV) infection.

          -  Receipt of systemic glucocorticoids within 1 month of study enrolment, or any other
             cytotoxic or immunosuppressive drug within 6 months of study enrolment.

          -  Any significant disorder of coagulation or treatment with Coumadin derivatives or
             heparin.

          -  Administration of any registered vaccine within 30 days before study enrolment or
             planned administration within the first vaccination up to blood sampling at Day 42
             and within 30 days prior to blood sampling at Day 182.

          -  Use of any investigational or non-registered product within 30 days prior to study
             enrolment or planned use during the study period.

          -  History of previous H5N1 vaccination, or history of H5N1 influenza infection.

          -  Receipt of any immunoglobulins and/or any blood products within 6 months of study
             enrolment or planned administration of any of these products during the study period.

          -  Any known or suspected allergy to any constituent of influenza vaccines or component
             used in the manufacturing process of the study vaccine, a history of
             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse
             reaction to a previous influenza vaccine.

          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin test result
             prior to the time of first vaccination.

          -  Lactating or nursing.

          -  Women of child-bearing potential who lack a history of reliable contraceptive
             practices. The provision of this history does NOT replace the requirement to perform,
             and obtain negative results in pregnancy urine tests prior to treatments; all women
             will have urine pregnancy tests regardless of their status.

          -  Known receipt of analgesic or antipyretic medication on the day of treatment (Day 0).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>204-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Nagai H, Ikematsu H, Tenjinbaru K, Maeda A, Dramé M, Roman FP. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC Infect Dis. 2010 Nov 25;10:338. doi: 10.1186/1471-2334-10-338.</citation>
    <PMID>21108818</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2008</firstreceived_date>
  <firstreceived_results_date>December 20, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Pandemic Influenza</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Influenza A (H5N1) 20-40 Years Group</title>
          <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Influenza A (H5N1) 41-64 Years Group</title>
          <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49">to Day 182</participants>
                <participants group_id="P2" count="50">to Day 182</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza A (H5N1) 20-40 Years Group</title>
          <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Influenza A (H5N1) 41-64 Years Group</title>
          <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31.1" spread="5.69"/>
                <measurement group_id="B2" value="49.6" spread="6.04"/>
                <measurement group_id="B3" value="40.3" spread="10.98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="57"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia/05/2005 antigen (A/Indonesia).</description>
        <time_frame>At Day 0 and Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain</title>
            <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia/05/2005 antigen (A/Indonesia).</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Indonesia at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  <measurement group_id="O2" value="5.4" lower_limit="5.0" upper_limit="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156.8" lower_limit="105.8" upper_limit="232.3"/>
                  <measurement group_id="O2" value="142.1" lower_limit="104.0" upper_limit="194.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for H5N1 HI Antibodies</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for H5N1 HI Antibodies</title>
            <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HI Antibody Seroconversion Factors for H5N1 HI Antibodies</title>
        <description>Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 0 and Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HI Antibody Seroconversion Factors for H5N1 HI Antibodies</title>
            <description>Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Fold Increase</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31.4" lower_limit="21.2" upper_limit="46.5"/>
                  <measurement group_id="O2" value="26.2" lower_limit="19.2" upper_limit="35.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroprotected for H5N1 HI Antibodies</title>
        <description>A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroprotected for H5N1 HI Antibodies</title>
            <description>A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Day 42. The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 0, Day 21 and Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component on Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain</title>
            <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Indonesia at Day 0 [N=50; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  <measurement group_id="O2" value="5.4" lower_limit="5.0" upper_limit="5.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 21 [N=50; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.8" lower_limit="11.0" upper_limit="22.8"/>
                  <measurement group_id="O2" value="15.4" lower_limit="10.7" upper_limit="22.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 182 [N=49; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.6" lower_limit="17.3" upper_limit="38.1"/>
                  <measurement group_id="O2" value="37.4" lower_limit="27.5" upper_limit="50.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for H5N1 HI Antibodies</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 21 and Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component on Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for H5N1 HI Antibodies</title>
            <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Indonesia at Day 21 [N=50; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 182 [N=49; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factors for H5N1 HI Antibodies</title>
        <description>Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 21 and Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component on Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroconversion Factors for H5N1 HI Antibodies</title>
            <description>Seroconversion factors (SCF) were defined as the fold increase in serum H5N1 HI antibody GMTs post-vaccination compared to Day 0, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Fold Increase</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Indonesia at Day 21 [N= 50; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.2" lower_limit="2.2" upper_limit="4.6"/>
                  <measurement group_id="O2" value="2.8" lower_limit="2.0" upper_limit="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 182 [N=49;50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.1" lower_limit="3.5" upper_limit="7.6"/>
                  <measurement group_id="O2" value="6.9" lower_limit="5.1" upper_limit="9.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for H5N1 HI Antibodies</title>
        <description>A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 0, Day 21 and Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component on Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroprotected for H5N1 HI Antibodies</title>
            <description>A seroprotected subject was defined as a subject with a serum H5N1 HI antibody titer greater than or equal to 1:40, at Days 21 and 182. The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Indonesia at Day 0 [N=50; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 21 [N=50; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 182 [N=49; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers for Serum Anti-H5N1 Neutralising Antibodies</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 0, Day 42 and Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component on Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Titers for Serum Anti-H5N1 Neutralising Antibodies</title>
            <description>Antibody titers were expressed as Geometric mean titers (GMTs). The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Indonesia at Day 0 [N= 50; 49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.4" lower_limit="13.6" upper_limit="15.2"/>
                  <measurement group_id="O2" value="18.3" lower_limit="15.4" upper_limit="21.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 42 [N=50; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="579.6" lower_limit="466.5" upper_limit="720.0"/>
                  <measurement group_id="O2" value="473.8" lower_limit="379.9" upper_limit="591.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 182 [N=49; 50]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="240.5" lower_limit="210.3" upper_limit="275.0"/>
                  <measurement group_id="O2" value="240.1" lower_limit="210.0" upper_limit="274.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Serum Anti-H5N1 Neutralising Antibodies</title>
        <description>A seroconverted subject was defined as a subject with a minimum 4 fold increase in titer at post-vaccination for neutralising antibody response at Days 42 and 182.
The H5N1 vaccine strain included A/Indonesia antigen.</description>
        <time_frame>At Day 42 and Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-To-Protocol (ATP) cohort for persistence which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and assay results were available for antibodies against the study vaccine antigen component on Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for Serum Anti-H5N1 Neutralising Antibodies</title>
            <description>A seroconverted subject was defined as a subject with a minimum 4 fold increase in titer at post-vaccination for neutralising antibody response at Days 42 and 182.
The H5N1 vaccine strain included A/Indonesia antigen.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Indonesia at Day 42 [N=50; 49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Indonesia at Day 182 [N=49; 49]</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
        <description>Biochemical and haematological parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), basophils (BAS) and blood urea nitrogen (BUN ). Categories = unknown, below, within, or above the normal ranges.</description>
        <time_frame>At Day 0, Day 7 and Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
            <description>Biochemical and haematological parameters assessed in blood samples include alanine aminotransferase (ALT), aspartate aminotransferase (AST), basophils (BAS) and blood urea nitrogen (BUN ). Categories = unknown, below, within, or above the normal ranges.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AST [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
        <description>Biochemical and haematological parameters assessed in blood samples include creatinine (CREA), eosinophils (EOS), hemoglobin (HB) and hematocrit (HC).
Categories = unknown, below, within, or above the normal ranges.</description>
        <time_frame>At Day 0, Day 7 and Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
            <description>Biochemical and haematological parameters assessed in blood samples include creatinine (CREA), eosinophils (EOS), hemoglobin (HB) and hematocrit (HC).
Categories = unknown, below, within, or above the normal ranges.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CREA [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HB[Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC[Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
        <description>Biochemical and haematological parameters assessed in blood samples include lymphocytes (LYM), monocytes (MON) and neutrophils (NEU).
Categories = unknown, below, within, or above the normal ranges.</description>
        <time_frame>At Day 0, Day 7 and Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
            <description>Biochemical and haematological parameters assessed in blood samples include lymphocytes (LYM), monocytes (MON) and neutrophils (NEU).
Categories = unknown, below, within, or above the normal ranges.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>LYM [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
        <description>Biochemical and haematological parameters assessed in blood samples include lymphocytes (LYM), monocytes (MON) and neutrophils (NEU).
Categories = unknown, below, within, or above the normal ranges.</description>
        <time_frame>At Day 0, Day 7 and Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group.</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group.</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Biochemical and Haematological Laboratory Abnormalities</title>
            <description>Biochemical and haematological parameters assessed in blood samples include lymphocytes (LYM), monocytes (MON) and neutrophils (NEU).
Categories = unknown, below, within, or above the normal ranges.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>PLA [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC[Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC[Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC[Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC[Unknown] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Unknown] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Unknown] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Below] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Below] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Below] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Within] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Within] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Within] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Above] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Above] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC [Above] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Normal or Abnormal Urine Values</title>
        <description>Urine parameters assessed were blood, glucose, protein and urobilinogen. Categories = negative, positive</description>
        <time_frame>At Day 0, Day 7 and Day 42</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Normal or Abnormal Urine Values</title>
            <description>Urine parameters assessed were blood, glucose, protein and urobilinogen. Categories = negative, positive</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Blood [Negative] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood [Positive] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood [Negative] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood [Positive] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood [Negative] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood [Positive] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose [Negative] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose [Positive] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose [Negative] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose [Positive] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose [Negative] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose [Positive] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein [Negative] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein [Positive] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein [Negative] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein [Positive] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein [Negative] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Protein [Positive] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen [Negative] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen [Positive] at Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen [Negative] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen [Positive] at Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen [Negative] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urobilinogen [Positive] at Day 42</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling/induration. Any=any solicited local symptom reported regardless of their intensity. Grade 3 pain= significant pain at rest that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness and swelling/induration=redness and swelling/induration above 100 millimetres (mm).</description>
        <time_frame>During the 7-day post vaccination period (Days 0-6) after any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed were pain, redness and swelling/induration. Any=any solicited local symptom reported regardless of their intensity. Grade 3 pain= significant pain at rest that prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness and swelling/induration=redness and swelling/induration above 100 millimetres (mm).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any swelling/induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 swelling/induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed were fatigue, headache, joint pain, muscle aches, shivering, increase sweating and fever. Any=any solicited general symptom reported regardless of their intensity grade or their relationship to vaccination. Any fever was ≥ 38.0 degrees celsius (°C). Grade 3 = general symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever was≥ 39.0°C. Related= general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the 7-day post vaccination period (Days 0-6) after any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
            <description>Solicited general symptoms assessed were fatigue, headache, joint pain, muscle aches, shivering, increase sweating and fever. Any=any solicited general symptom reported regardless of their intensity grade or their relationship to vaccination. Any fever was ≥ 38.0 degrees celsius (°C). Grade 3 = general symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever was≥ 39.0°C. Related= general symptom assessed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any joint pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 joint pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related joint pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any increase sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 increase sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related increase sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
        <time_frame>During the 21-day (Days 0-20) following vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
            <description>Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any unsolicited AE (s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 unsolicited AE (s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related unsolicited AE (s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
        <description>Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
        <time_frame>From Day 0 to Day 83 following vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
            <description>Unsolicited AE is any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any unsolicited AE (s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 unsolicited AE (s</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related unsolicited AE (s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Medically-significant Conditions (MSCs)</title>
        <description>MSCs were defined as AEs with a medically-attended visit (s) i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination.</description>
        <time_frame>During the 182-day (Days 0-181) post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Medically-significant Conditions (MSCs)</title>
            <description>MSCs were defined as AEs with a medically-attended visit (s) i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the entire study period (Day 0 to Day 181)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza A (H5N1) 20-40 Years Group</title>
            <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Influenza A (H5N1) 41-64 Years Group</title>
            <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events = From Days 0-181. Systematically assessed frequent adverse events (AEs) = During the 7 day post vaccination period. Non-systematically assessed frequent AEs= During Days 0-20 and Days 0-84 post vaccination period respectively.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Influenza A (H5N1) 20-40 Years Group</title>
          <description>Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Influenza A (H5N1) 41-64 Years Group</title>
          <description>Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Assessed during Days 0-20 post vaccination period</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <description>Assessed during Days 0-83 post vaccination period</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Assessed during Days 0-83 post vaccination period</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Swelling/ Induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Increase Sweating</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <description>Assessed during Days 0-20 post vaccination period</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <description>Assessed during Days 0-20 post vaccination period</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <description>Assessed during Days 0-83 post vaccination period</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <description>Assessed during Days 0-83 post vaccination period</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Assessed during Days 0-20 post vaccination period</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Assessed during Days 0-83 post vaccination period</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Assessed during Days 0-83 post vaccination period</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Assessed during Days 0-83 post vaccination period</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
